Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation Meeting Abstract

  

Authors:	Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Döhner, H.; Pollyea, D. A.; McCloskey, J. K.; Odenike, O.; Lowenberg, B.; Ossenkoppele, G. J.; Patel, P.; Roshal, M.; Frattini, M. G.; Lersch, F.; Nabhan, S.; Almon, C.; Saatcioglu, D.; Zhang, V.; Cooper, M.; Kantarjian, H.; Tallman, M. S.
Abstract Title:	Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736398805008
DOI:	10.1182/blood-2021-146507
PROVIDER:	wos
Notes:	Meeting Abstract: 1276 -- Hybrid meeting, also took place online -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/198940